Abstract
DA-8159, a new phosphodiesterase 5 inhibitor, was assessed for its erectogenic potential by a penile erection test in rats, the relaxation of isolated rabbit corpus cavernosum (CC), and estimation of the intracavernous pressure (ICP) in the anesthetized dog. Oral administration of DA-8159 (0.3 to 1 mg/kg) increased the number of erections in rats with increasing dosage, with the highest penile erection index at 10 mg/kg. DA-8159 induced the relaxation of phenylephrine (PHE)-induced contractions in the rabbit CC and decreased the IC50 of the nitric oxide donor sodium nitroprusside (SNP) in a dose-dependent fashion. In pentobarbital-anesthetized dogs, the intravenous administration of DA-8159 (1≈300 μg/kg) potentiated the increase in ICP induced by the intracavernosal SNP in a dose-related manner. These findings suggest that DA-8159 has significant therapeutic potential in the treatment of erectile dysfunction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Urological Association Press Release. American Urological Association panel release treatment guidelines for impotence. 1996. November 4.
Benassi-Benelli, A., Ferrari, F. and Pellegrine-Quarantotti, B., Penile erection induced by apomorphine and N-n-propylapomorphine in rats.Arch. Int. Pharmacodyn. Ther., 2423, 241–242 (1979).
Boolell, M., Pearson, J., Gingell, J. C., Gepi-Attee, S., Wareham, K. and Price, D., Sildenafil (Viagra) is an effecacious oral therapy in diabetic patients with erectile dysfunction.Int. J. Impot. Res., 8, 186–191 (1996).
Bush, P. A., Aronson, W. J., Rajfer, J. and Ignarro, L. J., The L-argininenitric oxide-cyclic GMP pathway mediates inhibitory non-adrenergic non-cholinergic neurotransmission in the corpus cavernosum of human and rabbit.Circulation, 87 (Suppl. 5), V30-V32 (1993).
Butcher, R. W. and Sutherland, E. W., Adenosine 3′,5′-monophosphate in biological materials. II. The measurement of adenosine 3′,5′-monophosphate in tissues and the role of the cyclic nucleotide in the lipolytic response of fat to epinephrine.J. Biol. Chem., 237, 1244–1250 (1962).
Butler, R. N., Lewis, M. I., Hoffman, E. and Whitehead, E. D., Love and sex after 60: How to evaluate and treat the impotent older man.Geriatrics, 49, 27–32 (1994).
Conti, M., Nemoz, G., Sette, C. and Vicini, E., Recent progress in understanding the hormonal regulation of phosphodiesterases.Endocr. Rev., 16, 370–389 (1995).
Degerman, E., Belfrage, P. and Manganiello, V. C., Structure, localization, and regulation of cGMP-inhibited phospho-diesterase (PDE3).J. Biol. Chem., 272, 6823–6826 (1997).
Furlow, W. L., Prevalence of impotence in the United States.Medical Aspects of Human Sexuality, 19, 13–16 (1985).
Holmgren, B., Urba-Holmgren, R. L., Trucios, N., Zermeno, M. and Eguibar, J. R., Association of spontaneous and dopaminergic-induced yawning and penile erections in the rat.Pharmacol. Biochem. Behav., 22, 31–35 (1985).
Houslay, M. D., Compartmentalization of cyclic AMP phosphodiesterases, signalling ‘crosstalk’, desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP.Adv. Enzyme Regul., 35, 303–338 (1995).
Islam, M. W., Tariq, M., Ageel, A. M., Al-Said and Al-Yhya, A. M., Effect ofSalvia haematodes on sexual behavior of male rats.J. Ethanopharmacol., 33, 67–72 (1991).
Kim, N., Azadzoi, K. M., Goldstein, I. and Saenz de Tejada, I. A., A nitrix oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosal smooth muscle.J. Clin. Invest., 88, 112–118 (1991).
Koeneman, K. S., Mulhall, J. P. and Goldstein, I., Sexual health for the man at midlife: in-office workup.Geriatrics, 52, 76–86 (1997).
Leland, J., A pill for impotence? Newsweek, Nov. 17, 62–68 (1997).
Lipshultz, L. I., Injection therapy for erectile dysfunction.N. Engl. J. Med., 334, 913–914 (1996).
Montague, D. K., Barada, J. H., Belker, A. M., Levine, L. A., Nadig, P. W., Roehrborn, C. G., Sharlip, I. D. and Bennett, A. H., Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction.J. Urol. 156, 2007–2011 (1996).
Montorsi, F., Guazzoni, G., Rigatti, P. and Pozza, G., Pharmacological management of erectile dysfunction.Drugs, 50, 465–479 (1995).
Padma-Nathan, H., Hellstrom, W. J., Kaiser, F. E., Labasky, R. F., Lue, T. F., Nolten, W. E., Norwood, P. C., Peterson, C. A., Shabsigh, R. and Tam, P. Y., Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated urethral system for erection (MUSE) study Group.N. Engl. J. Med., 336, 1–7 (1997).
Taha, S. A., Ageel, A. M., Islam, M. W. and Ginawi, O. T., Effect of (−)-cathinone, a psychoactive alkaloid from khat (Catha Edulis Forsk.) and caffeine on sexual behavior in rats.Pharmacol. Res., 31, 299–303 (1995).
Thompson, W. J., Cyclic nucleotide phosphodiesterase: pharmacology, biochemistry and function.Pharmacol. Ther., 51, 13–33 (1991).
Trigo-Rocha, F., Aronson, W. J., Hohenfellner, M., Ignarro, L. J., Rajfer, J. and Lue, T. F., Nitric oxide of cGMP: mediators of pelvic nerve stimulated erection in dogs.Am. J. Physiol., 264, H419-H422 (1993).
Wagner, G. and Saenz de Tejada, I., Fortnightly review Update on male erectile dysfunction.Br. Med. J., 316, 678–682 (1998).
Werthman, P. and Rajfer, J., Muse therapy: preliminary clinical observations.Urol. 57, 809–811 (1997).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oh, T.Y., Kang, K.K., Ahn, B.O. et al. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 23, 471–476 (2000). https://doi.org/10.1007/BF02976575
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976575